Michel Bouvier, PhD

Michel Bouvier, PhD

Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal

Michel Bouvier, PhD, is Chief Executive Officer of the Institute for Research in Immunology and Cancer (IRIC) at the University of Montréal. His research focuses on deciphering the molecular mechanisms that regulate GPCRs. Many of his groundbreaking findings have over the years led to significant paradigm shifts in the field and paved the way for alternative strategies to develop novel and safer drugs targeting GPCRs. His contributions to the field of Molecular Pharmacology were recognized by the attribution of many awards.

the Management team

CEO & Chairman

Head of Medicinal Chemistry

Head of Biology & Pharmacology

Scientific Founder

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Board Of Directors​

President and CEO, Notch Therapeutics - Independent Board member

CEO & Chairman

CEO, Domain Therapeutics - Board member

Founder & CEO of Parthenon Therapeutics - Board member

Managing partner, Kurma Life Sciences Partners - Board member

Principal, Kurma Life Sciences Partners - Board member

Managing Partner & Co-Founder, Fountain Healthcare Partners - Board member

Senior Associate, Fountain Healthcare Partners - Board observer

Scientific and Clinical Advisors

Chairman of the Scientific Advisory Board

Stanford Univ, School of Med (US) | Rheumatology-SLE

John Hopkins Medicine (US) | Rheumatology-SLE

UMC Amsterdam (NL) | Rheumatology-SLE

Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris

Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam

Gardiner Professor of Biochemistry, and Deputy Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow

Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal